NATIONAL
HEALTHCARE 2023
- 30.11.2023
- Parking lot of the Rapira Shopping Centre 30.11.2023 at 09:00
- Date of the last day of registration for the tour 11.24.2023
One of the pharmaceutical industry’s main goals is to ensure the quality of drugs. The tour will provide an overview of all stages of drug production. Participants will visit the SDF (solid dosage form site), will be able to see the technological stages of the production of SDF (tablets and capsules), the ventilation and air conditioning system of production areas, laboratories, and warehouses, the chemical analytical laboratory, as well as facilities where drugs are analysed based on all relevant standards and pass through incoming control, process control, and output control.
Tour route:
Participants will be able to see the technological stages of the production of SDF (tablets and capsules) at the SDF site.
Ventilation and air conditioning system for production areas, laboratories, and warehouses
Chemical analytical laboratory (CAL)
The laboratory conducts analyses based on all relevant standards, as well as incoming control, process control, and output control.
Shuttles will be waiting for you at the pick-up point at the designated times. Please have your passport with you.
The Bright Way Group is a pharmaceutical holding whose development strategy aims to create a modern business ecosystem for the full-cycle production of medicinal products, from pharmaceutical substances to finished drugs.
Velpharm-M, which is part of the Bright Way Group, is a six-floor pharmaceutical research and production facility for the development and production of medicines with its own 33,700-square metre R&D centre located in the northwest section of the Alabushevo platform. Velpharm-M is the sixth plant that has been launched in the pharmaceutical cluster of the Technopolis Moscow Special Economic Zone.
Once it is fully developed, the enterprise’s portfolio will include more than 300 types of drugs from various pharmacotherapeutic groups.
In 2023–2024, Velpharm-M plans to commission 10 drug manufacturing lines and launch the production of more than 300 solid and sterile dosage forms, specifically drugs for the treatment of oncological diseases.
The plant will also manufacture drugs for the treatment of multiple sclerosis, chronic renal failure, respiratory diseases, cardiovascular diseases, and numerous other diseases. Many of these drugs have not previously been produced in Russia. The enterprise’s capacity will allow for annual production of up to 1.7 billion tablets, including film-coated ones, 180 million hard gelatine capsules, 45 million sachet powders, 1.7 million bottles of lyophilized products, 24 million bottles of eye drops, and 5 million prefilled syringes.
The products will be supplied to state-owned medical institutions. After Velpharm-M reaches full capacity, output will be 133.7 million packages per year. The use of high-tech production will reduce prices for a number of medicines, including those that are vital for the treatment of serious diseases.
At present, Velpharm-M has launched three solid dosage form lines (tablets and capsules) and one sterile dosage form line (bottles and syringes). In 2024, the company plans to commission four additional tablet dosage form lines (tablets, capsules, and sachets) and build a second production building to manufacture oncological and hormonal drugs.
One of the pharmaceutical industry’s main goals is to ensure the quality of drugs. The tour will provide an overview of all stages of drug production. Participants will visit the SDF (solid dosage form site), will be able to see the technological stages of the production of SDF (tablets and capsules), the ventilation and air conditioning system of production areas, laboratories, and warehouses, the chemical analytical laboratory, as well as facilities where drugs are analysed based on all relevant standards and pass through incoming control, process control, and output control.
Tour route:
Participants will be able to see the technological stages of the production of SDF (tablets and capsules) at the SDF site.
Ventilation and air conditioning system for production areas, laboratories, and warehouses
Chemical analytical laboratory (CAL)
The laboratory conducts analyses based on all relevant standards, as well as incoming control, process control, and output control.
Shuttles will be waiting for you at the pick-up point at the designated times. Please have your passport with you.
The Bright Way Group is a pharmaceutical holding whose development strategy aims to create a modern business ecosystem for the full-cycle production of medicinal products, from pharmaceutical substances to finished drugs.
Velpharm-M, which is part of the Bright Way Group, is a six-floor pharmaceutical research and production facility for the development and production of medicines with its own 33,700-square metre R&D centre located in the northwest section of the Alabushevo platform. Velpharm-M is the sixth plant that has been launched in the pharmaceutical cluster of the Technopolis Moscow Special Economic Zone.
Once it is fully developed, the enterprise’s portfolio will include more than 300 types of drugs from various pharmacotherapeutic groups.
In 2023–2024, Velpharm-M plans to commission 10 drug manufacturing lines and launch the production of more than 300 solid and sterile dosage forms, specifically drugs for the treatment of oncological diseases.
The plant will also manufacture drugs for the treatment of multiple sclerosis, chronic renal failure, respiratory diseases, cardiovascular diseases, and numerous other diseases. Many of these drugs have not previously been produced in Russia. The enterprise’s capacity will allow for annual production of up to 1.7 billion tablets, including film-coated ones, 180 million hard gelatine capsules, 45 million sachet powders, 1.7 million bottles of lyophilized products, 24 million bottles of eye drops, and 5 million prefilled syringes.
The products will be supplied to state-owned medical institutions. After Velpharm-M reaches full capacity, output will be 133.7 million packages per year. The use of high-tech production will reduce prices for a number of medicines, including those that are vital for the treatment of serious diseases.
At present, Velpharm-M has launched three solid dosage form lines (tablets and capsules) and one sterile dosage form line (bottles and syringes). In 2024, the company plans to commission four additional tablet dosage form lines (tablets, capsules, and sachets) and build a second production building to manufacture oncological and hormonal drugs.
One of the pharmaceutical industry’s main goals is to ensure the quality of drugs. The tour will provide an overview of all stages of drug production. Participants will visit the SDF (solid dosage form site), will be able to see the technological stages of the production of SDF (tablets and capsules), the ventilation and air conditioning system of production areas, laboratories, and warehouses, the chemical analytical laboratory, as well as facilities where drugs are analysed based on all relevant standards and pass through incoming control, process control, and output control.
